235 related articles for article (PubMed ID: 30196572)
21. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
[TBL] [Abstract][Full Text] [Related]
22. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
23. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
24. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
[TBL] [Abstract][Full Text] [Related]
25. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
[TBL] [Abstract][Full Text] [Related]
26. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
[TBL] [Abstract][Full Text] [Related]
27. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
28. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial.
Vos NS; Fagel ND; Amoroso G; Herrman JR; Patterson MS; Piers LH; van der Schaaf RJ; Slagboom T; Vink MA
JACC Cardiovasc Interv; 2019 Sep; 12(17):1691-1699. PubMed ID: 31126887
[TBL] [Abstract][Full Text] [Related]
30. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
31. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
32. A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
Ielasi A; Campo G; Rapetto C; Varricchio A; Cortese B; Brugaletta S; Geraci S; Vicinelli P; Scotto di Uccio F; Secco GG; Poli A; Nicolini E; Ishida K; Latib A; Tespili M
JACC Cardiovasc Interv; 2017 Sep; 10(18):1855-1864. PubMed ID: 28935077
[TBL] [Abstract][Full Text] [Related]
33. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
[TBL] [Abstract][Full Text] [Related]
34. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
[TBL] [Abstract][Full Text] [Related]
35. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold.
Chevalier B; Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Weng SC; Akodad M; Anderson J; Stone GW
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007283. PubMed ID: 31177821
[TBL] [Abstract][Full Text] [Related]
37. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.
Sim HW; Thong EH; Tan HC; Low AF; Lee CH; Chan MY; Tay EL; Loh PH; Chan KH; Loh JP
Cardiovasc Revasc Med; 2019 Sep; 20(9):739-743. PubMed ID: 30442536
[TBL] [Abstract][Full Text] [Related]
39. Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study.
van der Hoeven BL; Liem SS; Dijkstra J; Bergheanu SC; Putter H; Antoni ML; Atsma DE; Bootsma M; Zeppenfeld K; Jukema JW; Schalij MJ
JACC Cardiovasc Interv; 2008 Apr; 1(2):192-201. PubMed ID: 19463300
[TBL] [Abstract][Full Text] [Related]
40. One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study).
Ielasi A; Campo G; Cortese B; Leoncini M; Varricchio A; Brugaletta S; Favaretto E; Fineschi M; Piraino D; Calabria P; Granata F; Pisano F; Mussardo M; Latib A; Tespili M
Cardiovasc Revasc Med; 2019 Aug; 20(8):700-704. PubMed ID: 30314835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
